A
APELLIS PHARMACEUTICALS INC
NASDAQ: APLS (Apellis Pharmaceuticals, Inc.)
Kemas kini terakhir: semalam, 9:38AM23.63
1.44 (6.49%)
| Penutupan Terdahulu | 22.19 |
| Buka | 22.13 |
| Jumlah Dagangan | 3,875,513 |
| Purata Dagangan (3B) | 2,583,995 |
| Modal Pasaran | 2,989,790,720 |
| Harga / Pendapatan (P/E TTM) | 65.64 |
| Harga / Pendapatan (P/E Ke hadapan) | 46.30 |
| Harga / Jualan (P/S) | 2.69 |
| Harga / Buku (P/B) | 6.72 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 30 Oct 2025 |
| Margin Keuntungan | -28.83% |
| Margin Operasi (TTM) | -49.96% |
| EPS Cair (TTM) | -1.80 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -3.20% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 285.94% |
| Nisbah Semasa (MRQ) | 4.08 |
| Aliran Tunai Operasi (OCF TTM) | -8.29 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 45.63 M |
| Pulangan Atas Aset (ROA TTM) | -14.20% |
| Pulangan Atas Ekuiti (ROE TTM) | -103.82% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Apellis Pharmaceuticals, Inc. | Menaik | Menaik |
AISkor Stockmoo
1.1
| Konsensus Penganalisis | 3.5 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 1.0 |
| Osilator Teknikal | 2.0 |
| Purata | 1.13 |
|
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 13.69% |
| % Dimiliki oleh Institusi | 104.60% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Deep Track Capital, Lp | 30 Sep 2025 | 8,000,382 |
| Ecor1 Capital, Llc | 30 Sep 2025 | 3,447,156 |
| Siren, L.L.C. | 30 Sep 2025 | 2,578,396 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 52.00 (Baird, 120.06%) | Beli |
| Median | 40.50 (71.39%) | |
| Rendah | 18.00 (Goldman Sachs, -23.83%) | Jual |
| Purata | 36.50 (54.47%) | |
| Jumlah | 6 Beli, 1 Pegang, 1 Jual | |
| Harga Purata @ Panggilan | 21.76 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| JP Morgan | 05 Nov 2025 | 36.00 (52.35%) | Beli | 19.95 |
| Mizuho | 03 Nov 2025 | 19.00 (-19.59%) | Pegang | 20.69 |
| Baird | 31 Oct 2025 | 52.00 (120.06%) | Beli | 21.47 |
| Citigroup | 31 Oct 2025 | 45.00 (90.44%) | Beli | 21.47 |
| HC Wainwright & Co. | 31 Oct 2025 | 45.00 (90.44%) | Beli | 21.47 |
| TD Cowen | 31 Oct 2025 | 45.00 (90.44%) | Beli | 21.47 |
| Wells Fargo | 15 Oct 2025 | 32.00 (35.42%) | Beli | 25.22 |
| Goldman Sachs | 26 Sep 2025 | 18.00 (-23.83%) | Jual | 22.37 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 03 Dec 2025 | Pengumuman | The New England Journal of Medicine Publishes Positive Phase 3 VALIANT Results of EMPAVELI® (pegcetacoplan) for C3G and Primary IC-MPGN |
| 25 Nov 2025 | Pengumuman | Apellis Pharmaceuticals to Participate in Upcoming Investor Conferences |
| 12 Nov 2025 | Pengumuman | Apellis Announces 5-Year GALE Data Showing SYFOVRE® (pegcetacoplan injection) Delayed Progression of Geographic Atrophy by ~1.5 Years |
| 05 Nov 2025 | Pengumuman | Apellis Pharmaceuticals to Present at the Stifel 2025 Healthcare Conference |
| 30 Oct 2025 | Pengumuman | Apellis Pharmaceuticals Reports Third Quarter 2025 Financial Results |
| 20 Oct 2025 | Pengumuman | New One-Year Data Reinforcing the Robust and Sustained Efficacy of EMPAVELI® (pegcetacoplan) in C3G and Primary IC-MPGN to be Presented at ASN Kidney Week |
| 16 Oct 2025 | Pengumuman | Apellis Pharmaceuticals to Host Conference Call on October 30, 2025, to Discuss Third Quarter 2025 Financial Results |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |